PHPaul R. Harris

Paul R. Harris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul R. Harris has a total of 172 co-authors. Here are the top co-authors by number of shared publications:

  • Carolina Serrano H

    Pontificia Universidad Católica de Chile, Chile

    5 shared publications
  • Alex Godoy-Faúndez

    Research Center on Sustainability and Strategic Resource Management (CISGER). Faculty of Engineering, Universidad del Desarrollo. Avda. Plaza 700. Santiago de Chile. Chile

    3 shared publications
  • Andrea Villagrán

    Laboratorio de Inmunología e Infección Gastrointestinal, Departamento de Gastroenterología y Nutrición Pediátrica, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

    3 shared publications
  • Carmen Gloria González F

    Pontificia Universidad Católica de Chile, Chile

    3 shared publications
  • Carolina A. Serrano

    Department of Pediatric Gastroenterology and Nutrition, Pontificia Universidad Católica de Chile School of Medicine, Santiago, Chile

    3 shared publications
  • Carolina Serrano

    Laboratorio de Inmunología e Infección Gastrointestinal, Departamento de Gastroenterología y Nutrición Pediátrica, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

    3 shared publications

Latest Publications

  • Open Access

    Helicobacter pylori infection and UBT-13C values are associated with changes in body mass index in children and adults

    by María J. Bruera, María V. Amezquita, Arnoldo J. Riquelme, Carolina A. Serrano, Paul R. Harris

    Key words: Body Mass Index; Breath Tests; Urea; Helicobacter pylori


  • Open Access

    Adaptación a la realidad de Latinoamérica de la Guía Clínica NASPGHAN/ESPGHAN 2016 sobre Diagnóstico, Prevención y Tratamiento de Infección por Helicobacter pylori en Pediatría

    by Paul R Harris, Otto Gerardo Calderón-Guerrero, José Fernando Vera-Chamorro, Yalda Lucero, Margarita Vasquez, Silvio Kazuo Ogata, Diana Angulo, Armando Madrazo, José Gonzales, Anelsy Rivero, et al.

    Introducción: Las últimas guías clínicas conjuntas de NASPGHAN y ESPGHAN en relación a la infección por H. pylori publicadas el año 2016, contienen 20 afirmaciones que han sido cuestionadas en la práctica respecto a su aplicabilidad en Latinoamérica (LA); en particular en relación a la prevención del cáncer gástrico.Métodos: Se realizó un análisis crítico de la literatura, con especial énfasis en datos de LA y se estableció el nivel de evidencia y nivel de recomendación de las afirmaciones mas controversiales de las Guías Conjuntas. Se realizaron 2 rondas de votación de acuerdo a la técnica Delfi de consenso y se utilizó escala de Likert (de 0 a 4) para establecer el “grado de acuerdo” entre un grupo de expertos de SLAGHNP.Resultados: Existen pocos estudios en relación a diagnóstico, efectividad de tratamiento y susceptibilidad a antibióticos de H. pylori en pacientes pediátricos de LA. En base a estos estudios, extrapolaciones de estudios de adultos y la experiencia clínica del panel de expertos participantes, se realizan las siguientes recomendaciones. Recomendamos la toma de biopsias para test rápido de ureasa e histología (y muestras para cultivo o técnicas moleculares, cuando estén disponibles) durante la endoscopia digestiva alta sólo si en caso de confirmar la infección por H. pylori, se indicará tratamiento de erradicación. Recomendamos que centros regionales seleccionados realicen estudios de sensibilidad/resistencia antimicrobiana para H. pylori y así actúen como centros de referencia para toda LA. En caso de falla de erradicación de H. pylori con tratamiento de primera línea, recomendamos tratamiento empírico con terapia cuádruple con inhibidor de bomba de protones, amoxicilina, metronidazol y bismuto por 14 días. En caso de falla de erradicación con el esquema de segunda línea, se recomienda indicar un tratamiento individualizado considerando la edad del paciente, el esquema indicado previamente y la sensibilidad antibiótica de la cepa, lo que implica realizar una nueva endoscopía con extracción de muestra para cultivo y antibiograma o estudio molecular de resistencia. En niños sintomáticos referidos a endoscopía que tengan antecedente de familiar de primer o segundo grado con cáncer gástrico, se recomienda considerar la búsqueda de H. pylori mediante técnica directa durante la endoscopia (y erradicarlo cuando es detectado).Conclusiones: La evidencia apoya mayoritariamente los conceptos generales de las Guías NASPGHAN/ ESPGHAN 2016, pero es necesario adaptarlas a la realidad de LA, con énfasis en el desarrollo de centros regionales para el estudio de sensibilidad a antibióticos y mejorar la correcta selección del tratamiento de erradicación. En niños sintomáticos con antecedente familiar de primer o segundo grado de cáncer gástrico, se debe considerar la búsqueda y erradicación de H. pylori.


  • Adaptation to the reality of Latin America of the NASPGHAN/ESPGHAN 2016 Guidelines on the Diagnosis, Prevention and Treatment of Helicobacter pylori Infection in Pediatrics

    by Paul R. Harris, Otto Gerardo Calderon-Guerrero, Jose Fernando Vera-Chamorro, Yalda Lucero, Margarita Vasquez, Silvio Kazuo Ogata, Diana Angulo, Armando Madrazo, Jose Gonzales, Anelsy Rivero, et al.

    Introduction: The latest joint H. pylon NASPGHAN and ESPGHAN clinical guidelines published in 2016, contain 20 statements that have been questioned in practice regarding their applicability in Latin America (LA); in particular in relation to gastric cancer prevention. Methods: We conducted a critical analysis of the literature, with special emphasis on LA data and established the level of evidence and level of recommendation of the most controversial claims in the Joint Guidelines. Two rounds of voting were conducted according to the Delphi consensus technique and a Likert scale (from 0 to 4) was used to establish the "degree of agreement" among a panel of SLACHNP experts. Results: There are few studies regarding diagnosis, treatment effectiveness and susceptibility to antibiotics of H. pylon in pediatric patients of LA. Based on these studies, extrapolations from adult studies, and the clinical experience of the participating expert panel, the following recommendations are made. We recommend taking biopsies for rapid urease and histology testing (and samples for culture or molecular techniques, when available) during upper endoscopy only if in case of confirmed H. pylon infection, eradication treatment will be indicated. We recommend that selected regional centers conduct antimicrobial sensitivity/resistance studies for H. pylori and thus act as reference centers for all LA. In case of failure to eradicate H. pylori with first-line treatment, we recommend empirical treatment with quadruple therapy with proton pump inhibitor, amoxicillin, metronidazole, and bismuth for 14 days. In case of eradication failure with the second line scheme, it is recommended to indicate an individualized treatment considering the age of the patient, the previously indicated scheme and the antibiotic sensitivity of the strain, which implies performing a new endoscopy with sample extraction for culture and antibiogram or molecular resistance study. In symptomatic children referred to endoscopy who have a history of first or second degree family members with gastric cancer, it is recommended to consider the search for H. pylori by direct technique during endoscopy (and eradicate it when detected). Conclusions: The evidence supports most of the general concepts of the NASPGHAN/ESPGHAN 2016 Guidelines, but it is necessary to adapt them to the reality of LA, with emphasis on the development of regional centers for the study of antibiotic sensitivity and to improve the correct selection of the eradication treatment. In symptomatic children with a family history of first or second degree gastric cancer, the search for and eradication of H. pylori should be considered.


  • Open Access

    Maternal H. pylori is associated with differential fecal microbiota in infants born by vaginal delivery

    by Caroll D. Hernandez, Hakdong Shin, Paula A. Troncoso, Macarena H. Vera, Andrea A. Villagran, Selena M. Rodriguez-Rivera, Marlene A. Ortiz, Carolina A. Serrano, Arturo Borzutzky, Maria Gloria Dominguez-Bello, et al.

    Helicobacter pylori colonization may affect the mucosal immune system through modification of microbiota composition and their interactions with the host. We hypothesized that maternal H. pylori status affects the maternal intestinal microbiota of both mother and newborn. In this study, we determine the structure of the fecal microbiota in mothers and neonates according to maternal H. pylori status and delivery mode. We included 22 mothers and H. pylori infection was determined by fecal antigen test. Eleven mothers (50%) were H. pylori-positive (7 delivering vaginally and 4 by C-section), and 11 were negative (6 delivering vaginally and 5 by C-section). Stool samples were obtained from mothers and infants and the fecal DNA was sequenced. The fecal microbiota from mothers and their babies differed by the maternal H. pylori status, only in vaginal birth, not in C-section delivery. All 22 infants tested negative for fecal H. pylori at 15 days of age, but those born vaginally –and not those by C-section- showed differences in the infant microbiota by maternal H. pylori status (PERMANOVA, p = 0.01), with higher abundance of Enterobacteriaceae and Veillonella, in those born to H. pylori-positive mothers. In conclusion, the structure of the infant fecal microbiota is affected by the maternal H. pylori status only in infants born vaginally, suggesting that the effect could be mediated by labor and birth exposures.


  • Sweet Syndrome in Pediatric Active Ulcerative Colitis

    by Estefanía Miranda, Rodrigo Meza, Marianne Kolbach, Javiera Torres, Paul R. Harris


  • Eradication of Helicobacter pylori in Children Restores the Structure of the Gastric Bacterial Community to That of Noninfected Children

    by Carolina A. Serrano, Reinaldo Pierre, William J. Van Der Pol, Casey D. Morrow, Phillip D. Smith, Paul R. Harris


  • Open Access

    Helicobacter pylori infection is associated with an altered gastric microbiota in children

    by K.M. Brawner, R. Kumar, C.A. Serrano, T. Ptacek, E. Lefkowitz, C.D. Morrow, D. Zhi, Kr Kyanam-Kabir-Baig, L.E. Smythies, P.R. Harris, et al.


  • Functional gastrointestinal disorders in children from low socio‐economic status andHelicobacter pyloriinfection

    by F. Jaime, A. Villagrán, C. Hernández, M. Ortiz, C. Serrano, P. R. Harris

    Background: Most studies on functional gastrointestinal disorders (FGIDs) in children are based on data from the northern hemisphere. Scientific reports are arising in South American population, but little is still known about children from low socio‐economic status (SES), whereHelicobacter pyloriinfection is endemic. Our objective was to evaluate the prevalence of FGIDs in school children from low SES and its relationship withH. pyloriinfection.Methods: Children from 3 public schools of low SES from Santiago de Chile were included. Students completed the Rome III Questionnaire and a survey about other symptoms. Also, the13C urea breath test determined the presence ofH. pyloriinfection.Results: Five hundred six children were included, where 48% were male, with a median age of 15.7 years (range 7.1–19.6). Forty‐two percent had some FGID, aerophagia and functional constipation being the most frequent. Females (adjusted OR 1.5, 95% CI [1.1, 2.2]), those children with parents within the lowest level of education (adjusted OR 1.6, 95% CI: 1.1–2.4), and family history of gastric cancer (adjusted OR 1.9, 95% CI: 1.2–3.1) were related to FGIDs. The prevalence ofH. pyloriinfection was 55.9% (95% CI [50.7, 60.9]). In multivariable analysis, the presence of abdominal pain (OR 1.55, 95% CI [1.02, 2.36]), but not FGIDs, was related toH. pyloriinfection.Conclusions: FGIDs are common in low SES students. A low educational level of the household head, family history of gastric cancer. and being female are related to the development of FGIDs. In this study, no relationship between the presence ofH. pyloriand FGIDs was found.


  • Open Access

    La infección materna por Helicobacter pylori no aumenta el riesgo de contraer la bacteria en el primer trimestre de vida de sus lactantes

    by Paula Troncoso, Andrea Villagrán, Macarena Vera, Alberto Estay, Marlene Ortiz, Carolina Serrano, Caroll Hernández, Paul R. Harris

    H. pylori infection is acquired early in childhood. However, there is little information available regarding the role of breastfeeding and neonatal acquisition of the infection. To evaluate factors affecting the acquisition of H. pylori in newborns and infants from infected mothers. Consecutive mothers and their newborns were recruited into the study from the maternity unit, immediately after delivery. After signing informed consent, one stool sample from the mother was obtained before hospital discharge. Three stool samples of the newborns were then collected at home at 15, 60, and 90 days of life, for the detection of H. pylori antigen (Monoclonal HpSAg, sensitivity 94% and specificity 97%). The socio-epidemiological and biomedical variables were also analysed using a questionnaire. A total of 32 mother-child pairs (64 subjects) were enrolled. The mean maternal age was 30.1±5.1 years, with 53% vaginal delivery, and 85% exclusively breastfed. There were 13 (40%) infected mothers. No H. pylori infection was detected in newborns and infants up to 3 months of follow-up. No significant differences were found in socioeconomic level between infected versus non-infected mothers (both groups mostly in the very high socioeconomic category: 28% and 32%, respectively, P=.15) and in the number of family members between infected versus non-infected mothers (3.8±0.8 vs 4.2±1.8 persons, P=.18). Despite having a significant percentage of H. pylori-infected mothers, no newborn was infected at the third month of life. The protective role of breastfeeding cannot be ruled out.